Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NEV801 |
| Synonyms | |
| Therapy Description |
NEV801 is a multi-target inhibitor that selectively blocks the activity of topoisomerase I and II and activates transcription of HIF-1 and VEGF, thereby potentially resulting in anti-tumor activity (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NEV801 | NEV-801|NEV 801 | TOPO Inhibitor (Pan) 3 | NEV801 is a multi-target inhibitor that selectively blocks the activity of topoisomerase I and II and activates transcription of HIF-1 and VEGF, thereby potentially resulting in anti-tumor activity (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02797795 | Phase I | NEV801 | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers | Unknown status | USA | 0 |